Long-acting cabotegravir with rilpivirine ART has reduced the required dosing frequency from once daily to once every month or every two months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment.
Long-acting antiretrovirals and HIV treatment adherence Read More »
Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase of the FLAIR trial. The Phase IIIb SOLAR study comparing efficacy and safety of daily oral versus LA ART every 2 months allowed participants and
Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatment-naive patients and 74.5% of patients failing treatment presented with rilpivirine DRMs.
Injectable cabotegravir and rilpivirine (CAB/RPV), administered bimonthly by a medical provider, is convenient and improves privacy and medication management. One year after approval, myriad implementation barriers threaten the access and sustainability of this life-saving innovation: (1) eligibility issues (viral suppression, drug resistance, and failed oral regimens); (2) injection requires medical provider and transportation to facility; (3) strict
Cabotegravir (an integrase strand transfer inhibitor [INSTI] that is structurally similar to dolutegravir) and rilpivirine (a nonnucleoside reverse transcriptase inhibitor [NNRTI]) formulated as a nanoparticle suspension for intramuscular injection (CAB + RPV LA) are the first complete long-acting maintenance antiretroviral treatment (ART) approved for clinical use. To date, the drugs have not been coformulated, so
Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities Read More »
Long-acting (LA) intramuscular cabotegravir and rilpivirine are prone to drug-drug interactions (DDI). However, given the long dosing interval, the conduct of clinical DDIs studies with LA antiretrovirals is challenging. We performed virtual clinical DDI studies using physiologically based pharmacokinetic (PBPK) modeling to provide recommendations for the management of DDIs with strong or moderate inducers such
Long-acting injectable antiretroviral therapy (LAI-ART) for the treatment and prevention of human immunodeficiency virus (HIV) holds great potential to shift treatment paradigms by offering an alternative to daily oral medication. However, significant challenges at the drug, patient, and system levels risk impeding the uptake and implementation of LAI-ART. This review aims to describe the known
Currently, there is a single option for a complete parenteral HIV antiretroviral therapy (ART) regimen. Cabotegravir-rilpivirine is a complete HIV ART regimen combining an extended-release injectable integrase strand inhibitor (INSTI) solution (cabotegravir) with an extended-release injectable nonnucleoside reverse transcriptase inhibitor (NNRTI) solution, which allows for once-a-month dosing.
Under a single-patient request program sponsored by ViiV Healthcare and Janssen, doctors can request the compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for patients living with HIV-1. Results are documented within this paper.
This study investigates the impact of the age at which HIV was acquired on adherence.
